| pubmed-article:7252979 | pubmed:abstractText | Four analogues of [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid),4-valine,8-D-arginine]vasopressin [d-(CH2)5 VDAVP] and four analogues of its L-arginine isomer d(CH2)5 VAVP with O-methyl-, O-ethyl, O-isopropyl, and O-n-propyltyrosine substituents at position 2 were prepared by the solid-phase method using a slightly modified reoxidation procedure following deblocking with sodium in liquid ammonia to overcome losses due to insolubility. These analogues are the following: 1, d(CH2)5Tyr(Me)VDAVP;2, d(CH2)5Tyr(Et)VDAVP; 3, d(CH2)5Tyr(i-Pr)VDAVP; 4, d(CH2)5Tyr(n-Pr)VDAVP; 5, d(CH2)5Tyr(Me)VAVP; 6, d(CH2)5Tyr(Et)VAVP; 7, d(CH2)5Tyr(i-Pr)VAVP; 8, d(CH2)5Tyr(n-Pr)VAVP. These analogues were tested for agonistic and antagonistic activities in rat antidiuretic and rat vasopressor assay systems. All eight analogues cause a transient antidiuresis when injected intravenously and effectively antagonize antidiuretic responses to subsequent injections of arginine-vasopressin (AVP). They exhibit the following antiantidiuretic pA2 values: 1, 6.68 +/- 0.11; 2, 7.10 +/- 0.08; 3, 6.88 +/- 0.07; 4, 6.67 +/0 0.05; 5, 7.35 +/- 0.06; 6, 7.57 +/- 0.06; 7, 7.32 +/- 0.10; 8, 7.29 +/- 0.07. They are also highly effective antagonists of the vasopressor responses to AVP, with antivasopressor pA2 values in the range of 7.86 to 8.44. These findings indicate tht in this series O-ethyl substitution on the tyrosine at position 2 is optimal for antiantidiuretic potency and that L-arginine is far superior to D-arginine in this regard also. Thus, d(CH2)5Tyr(Et)VAVP with an antiantidiuretic pA2 of 7.57 +/- 0.06 is the most potent of these eight antidiuretic antagonists. These are the first known effective antagonists of in vivo antidiuretic responses to AVP. They are, thus, potentially useful pharmacological tools for studies on the roles of AVP in regulating water balance in normal and pathophysiological states in animals and in humans. They also serve as excellent lead compounds for the design of even more potent antagonists for potential therapeutic use for the treatment of hyponatremia secondary to inappropriate secretion of the antidiuretic hormone (SIADH or the Schwartz-Barter syndrome). | lld:pubmed |
